+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure



Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure



Journal of the American Heart Association 1(5): E000760



Galectin-3 (GAL-3), a β-galactoside-binding protein, is a new clinical biomarker believed to reflect cardiac remodeling/fibrosis in patients with heart failure (HF). Plasma GAL-3 is inversely related to renal function. It is not known whether the relationship between renal function and GAL-3 is influenced by clinical decompensation, type of HF, or the presence or absence of clinical HF. Patients were prospectively categorized as having acute decompensated HF or stable HF on the basis of clinical status and as having HF with reduced left ventricular ejection fraction or HF with preserved left ventricular ejection fraction. Plasma GAL-3 was measured by enzyme-linked immunosorbent assay in patients with HF (n=75), control patients without HF (n=32), and control patients without HF with moderate renal insufficiency (n=12). Compared to controls without HF (14±4 ng/mL), GAL-3 was higher in patients with both acute decompensated HF (23±11 ng/mL) and stable HF (22±10 ng/mL) (P<0.001 versus controls for both) but did not differ between acute decompensated HF and stable HF (P=0.75). Likewise, GAL-3 was elevated in both HF with preserved left ventricular ejection fraction (23±9 ng/mL) and HF with reduced left ventricular ejection fraction (22±11 ng/mL) (P<0.001 versus controls for both) but did not differ between HF with preserved ejection fraction and HF with reduced ejection fraction (P=0.37). GAL-3 correlated strongly with estimated glomerular filtration rate, both in patients with HF (r=-0.75, P<0.001) and in patients without HF (r=-0.82, P<0.001), and this relationship was unaffected by the presence or absence of clinical HF. Plasma GAL-3 is inversely related to renal function in patients with and without clinical HF. Concentrations of plasma GAL-3 do not seem to depend on the level of compensation or type of HF. Furthermore, the relationship between GAL-3 and renal function seems to be affected little or not at all by the presence or absence of clinical HF.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055471033

Download citation: RISBibTeXText

PMID: 23316284

DOI: 10.1161/jaha.112.000760


Related references

Heart failure (acute heart failure, chronic heart failure; left ventricular failure, right ventricular failure; systolic heart failure, diastolic heart failure; high output heart failure, low output heart failure). Ryoikibetsu Shokogun Shirizu 1996(12): 107-109, 1996

Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). Jacc. Heart Failure 3(3): 245-252, 2015

Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure 19(7): 821-836, 2017

Symposium on pathophysiology of congestive heart failure. 1. Relationship of renin-angiotensin-aldosterone system to cardio-renal hemodynamics on chronic congestive heart failure. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 62(12): 1609-1614, 1973

Clinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failure. European Journal of Heart Failure 17(9): 979-983, 2016

Data on clinical characteristics of a heart failure patients' cohort with reduced ejection fraction and analysis of the circulating values of five different heart failure biomarkers; high sensitivity troponin T, galectin-3, C-terminal propeptide of type I procollagen, soluble AXL and BNP. Data in Brief 9: 876-882, 2016

Effect of Trimetazidine on functional status and left ventricular function in non-valvular heart failure patients Results of Ajmer Heart Failure Registry. Indian Heart Journal 69: S88-S89, 2017

Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). European Heart Journal 27(10): 1216-1222, 2006

The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The united kingdom heart failure evaluation and assessment of risk trial (UK-HEART). European Heart Journal 20(18): 1335-1341, 1999

Effects of heart failure status on electrocardiogram precordial leads and their value for monitoring body fluid changes in heart failure patients. International Journal of Cardiology 152(1): 113-115, 2011

Trying to Stay Afloat: Reducing Heart Failure Hospitalizations Among Heart Failure with Preserved Ejection Fraction Patients by Utilization of an Outpatient Heart Failure Bridge Clinic. Journal of Cardiac Failure 24(8): S72-S73, 2018

Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure 19(3): 437-437, 2017

Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure 18(7): 859-868, 2017

Should heart failure be regarded as a terminal illness requiring palliative care? A study of heart failure patients', carers' and clinicians' understanding of heart failure prognosis and its management. Bmj Supportive and Palliative Care 7(4): 464-469, 2017

Phenomenon of paradoxical improvement in renal function defined by a decreased concentration of serum creatinine despite heart failure worsening in patients with mild-to-moderate heart failure. European Heart Journal 34(Suppl 1): P5762-P5762, 2013